An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.

Trial Profile

An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Diphtheria-tetanus vaccine; Interferon; Keyhole limpet haemocyanin; Pneumococcal vaccine
  • Indications Diphtheria; Multiple sclerosis; Pneumococcal infections; Tetanus
  • Focus Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 23 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 09 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 04 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Jul 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top